Clinical Trials Logo

Clinical Trial Summary

Patients with acute lymphoblastic leukaemia or very aggressive lymphoma and documented isolated CNS relapse or CNS relapse combined with other relapse sites should receive therapy with intrathecal DepoCyte at least once. Treatment may be repeated during induction phase each 2 weeks and monthly during maintenance phase. The study aim is to replace the usual 2-3 weekly applications of intrathecal triple therapy with one application of DepoCyte. Primary objective is the response rate after one application of DepoCyte. Further objectives are the compilation of data regarding safety and toxicity


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT00199108
Study type Interventional
Source Goethe University
Contact
Status Completed
Phase Phase 2/Phase 3
Start date April 2004
Completion date June 2008

See also
  Status Clinical Trial Phase
Completed NCT00199056 - German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (06/99) Phase 4
Completed NCT00199043 - Treatment of Hyperuricemia With Rasburicase in Patients With Acute Lymphoblastic Leukemia or High Grade Lymphoma Phase 3
Completed NCT00198978 - German Multicenter Trial for Treatment of Elderly Patients With Newly Diagnosed Acute Lymphoblastic Leukemia Phase 4
Completed NCT00199095 - Treatment of Elderly Patients (>65 Years) With Acute Lymphoblastic Leukemia Phase 4
Completed NCT00199004 - Trial for Treatment of Adult Patients With Standard Risk Acute Lymphoblastic Leukemia With Chemotherapy and Rituximab Phase 4
Completed NCT00198991 - German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (07/2003) Phase 4
Completed NCT00199069 - German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (05/93) Phase 4